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Positron emission tomography (PET) using the radiopharmaceutical 18F-2-deoxy-D-glucose (FDG), a D-glucose analog, has been shown by numerous studies to predict
prognosis in patients with non-small cell lung cancer.1–6 The study by Pastorino et al.7
reported in this issue of the Journal of Thoracic Oncology confirms the utility of
FDG-PET in predicting prognosis in patients with primary lung cancer and provides new
information about FDG-PET in a computed tomography (CT) screening program. This
study, initiated in Italy in 2000 and comprising a population of 1035 at high risk for lung
cancer, evaluated whether the standardized uptake value (SUV) was predictive of
long-term survival in 11 patients who had primary lung cancers at initial CT and in 27
patients with lung cancers detected by annual CT screening. Pastorino et al. reported that
the SUV correlated highly with survival in the 34 patients with lung cancer: the 5-year
survival was 100% for SUV 2.5, 60% for SUV 2.5 and 8, and 20% for SUV 8.
Interestingly, although all cases with a SUV2.5 were stage I, only half of stage I tumors
had a SUV2.5. In addition, 15% of the patients with a SUV8 and poor prognosis were
stage I. The results of this study, arguably the best data available on the use of PET in a
CT screening program, are interesting and suggest that metabolic assessment of biologic
behavior may improve the clinical management of patients with lung cancers detected by
screening and address the issue of potential over diagnosis of lung cancer and over
treatment in screening trials. Specifically, as stated by the authors, FDG-PET could reduce
the risk of unnecessary treatment, such as lobectomy for indolent disease, or could result
in the implementation of targeted systemic therapy for patients with a high risk of early
metastatic disease, potentially including those with early stage disease and a high SUV.
Pertaining to the evaluation of nodules detected on CT screening, this study
indicates that FDG-PET has a useful diagnostic role and is effective in reducing the
number of patients undergoing interventional procedures to establish the diagnosis. In this
regard, FDG-PET imaging was performed in 68 patients with nodules7 mm in diameter,
and the yield in distinguishing malignant from benign nodules was high (sensitivity 94%,
specificity 82%, accuracy 88%, positive predictive value 84%, and negative predictive
value 93%). The potential importance of FDG-PET in improving diagnostic accuracy is
emphasized by the large number of benign, noncalcified nodules that are detected by CT
in screening trials. For instance, after five annual CT examinations in a prospective
screening trial for lung cancer, 3356 noncalcified lung nodules were identified, whereas
only 68 lung cancers were diagnosed.8 Furthermore, the potential reduction in over
treatment because of the incorporation of FDG-PET imaging into the management
algorithm of patients with nodules is important because, despite stringent criteria restrict-
ing the performance of a biopsy of a lung nodule, it has been reported that 8% of biopsied
nodules detected by a CT screening trial are benign.9
It is essential to emphasize that the results reported by Pastorino et al. are in contrast
to the experience of Lindell et al., where the poor sensitivity of FDG-PET in diagnosing
lung cancer in nodules detected on screening CT raised questions about its usefulness in
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preoperative management.10 In this regard, Lindell et al.
reported that FDG-PET was negative in 32% of the 22 lung
cancers detected by screening CT. The authors surmise that
because screening detects a higher percentage of small tu-
mors and low-grade tumors, the limitations of FDG-PET in
diagnosing lung cancer are amplified in a screened popula-
tion. The reasons for the diagnostic discrepancy of the two
studies are unclear but may be due to differences in method-
ology as well as morphology and histology of the nodules. In
the study by Pastorino et al., FDG-PET imaging was included
in the diagnostic protocol from the beginning of the trial,
whereas in the study by Lindell et al. FDG-PET was per-
formed at the discretion of the referring physician. FDG-PET
imaging occurred in only approximately one-third of the
patients with lung cancer in the study by Lindell et al. and
bias in selecting which nodules were evaluated by FDG-PET
may have occurred. In addition, eight of 22 nodules in the
study by Lindell et al. were semisolid or ground glass in
attenuation (not specified by Pastorino et al.) and, although
unclear, there appears to have been a higher proportion of
bronchioloalveolar cell carcinomas, factors that may have
contributed to the high number of false negative PET scans.
A limitation of the study by Pastorino et al. is the
relatively small number of patients with primary cancers
studied and the performance of FDG-PET only in those
patients with nodules of 7 mm or greater in diameter. Al-
though this size delineation is understandable, considering
the inherent lack of resolution of FDG-PET imaging, the
management of nodules 5 mm in diameter and 7 mm is
not clearly addressed (nodules with a maximum diameter of
5 mm were considered benign and the authors state that the
results of their trial confirm the validity of this assumption).
Furthermore, it is unfortunate that Pastorino et al. did not
report a subanalysis of those patients with lung cancer at
baseline screening and those detected at subsequent annual
screening as the information obtained in the latter group
could potentially have more precisely delineated the role of
FDG-PET in the management and prognosis of incidence
nodules in screening trials.
In summary, the authors have shown that the FDG-PET
imaging can predict prognosis in patients with lung cancer
detected in a CT screening trial. Specifically, a low SUV is
predictive of long-term survival, whereas a high SUV por-
tents a poor outcome. Besides confirming the results of
previous studies regarding SUV and prognosis, the authors
have also contributed to a better understanding of the role of
FDG-PET imaging in the diagnosis and management of
nodules detected in a CT screening trial for lung cancer.
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